Quentmeier et al., using methylation-sensitive enzymes targeting CpG sites inside the 3′translated exon 2 sequence, showed that 28.6% of MPN patients had methylation of SOCS2 [30] (Figure S2). The gene discussed is SOCS2; the disease is myeloproliferative disorder.